A Phase 1 Single and Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Subjects
This is a first-in-human, two-part, Phase 1 study that will characterize the safety, tolerability, PK, and immunogenicity of HuL001.
100 项与 上海毅勤生物科技有限公司 相关的临床结果
0 项与 上海毅勤生物科技有限公司 相关的专利(医药)
100 项与 上海毅勤生物科技有限公司 相关的药物交易
100 项与 上海毅勤生物科技有限公司 相关的转化医学